.ANALYSIS EMPHASIZE.16 Oct 2024.
In the NIAGARA trial, the add-on of perioperative durvalumab to standard therapy for muscle-invasive bladder cancer enhanced event-free as well as on the whole survival, denoting a new therapy option for this disorder.